Abstract: The present disclosure relates to methods of determining and administering a treatment course of action. In particular, the present disclosure relates to compositions and methods for monitoring and treating neurological damage (e.g., stroke), for example, with anti-inflammation therapy.

Abstract: Disclosed herein is a method for treating renal disease in a subject that involves treating the subject with an effective amount of a compound of the formula (I). The disclosed method can in some embodiments, be used to treat any renal disease involving mitochondrial dysfunction. For example, in some embodiments, the renal disease involves acute kidney injury. As another example, in some embodiments, the renal disease involves diabetic kidney disease. In some embodiments, the renal disease is a glomerular disease (e.g. focal segmental glomerular sclerosis). In some embodiments, the renal disease is a renal vascular disease.

Abstract: Provided herein are compositions and methods for delivering pharmaceutical agents to the kidney. In particular, provided herein are nanoparticle formulations of ?2 adrenergic agonists for use in treating and preventing kidney damage or disease.

Abstract: The present invention provides methods of detecting mitochondrial dysfunction or acute kidney injury (AKI) by measuring the urinary protein levels of the ATP synthase (ATPS) beta subunit or cleavage products thereof in a subject.

Abstract: Disclosed herein are compositions and methods for promoting the repair and regeneration of injured tissues, such as injuries resulting from ischemic damage.